Carola Berking

Carola Berking

Erlangen, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 401 publications

AI-Assisted Line-Field Confocal Optical Coherence Tomography to Detect Subclinical Basal Cell Carcinoma.

AI-Assisted Line-Field Confocal Optical Coherence Tomography to Detect Subclinical Basal Cell Carcinoma.

Journal: JAMA dermatology
Published: August 19, 2026

How much sweating is enough? Predicting thermoregulatory capacity in patients with ectodermal dysplasia based on a minimal pilocarpine-induced sweat volume.

How much sweating is enough? Predicting thermoregulatory capacity in patients with ectodermal dysplasia based on a minimal pilocarpine-induced sweat volume.

Journal: Frontiers in pediatrics
Published: July 10, 2026

Management of Facial Immune Checkpoint Inhibitor-Induced Vitiligo with Topical Ruxolitinib: Quantitative Assessment Using a Semi-Automatic Tool.

Management of Facial Immune Checkpoint Inhibitor-Induced Vitiligo with Topical Ruxolitinib: Quantitative Assessment Using a Semi-Automatic Tool.

Journal: Current oncology (Toronto, Ont.)
Published: April 16, 2026

Transforming tumor cells into professional antigen-presenting cells using poly(β-amino ester) nanoparticles to deliver CD80-encoding mRNA.

Transforming tumor cells into professional antigen-presenting cells using poly(β-amino ester) nanoparticles to deliver CD80-encoding mRNA.

Journal: Nanoscale horizons
Published: April 12, 2026

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.

Journal: Future oncology (London, England)
Published: March 31, 2026

Organ Involvement and Treatment Response across Cutaneous Sarcoidosis Subtypes.

Organ Involvement and Treatment Response across Cutaneous Sarcoidosis Subtypes.

Journal: Acta dermato-venereologica
Published: March 11, 2026

Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study.

Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study.

Journal: Journal for immunotherapy of cancer
Published: February 23, 2026

Real-world treatment patterns in stage III and IV melanoma patients: insights from a global multi-center chart review study.

Real-world treatment patterns in stage III and IV melanoma patients: insights from a global multi-center chart review study.

Journal: Frontiers in immunology
Published: February 18, 2026

Immune checkpoint inhibitor-induced bullous pemphigoid

Immune checkpoint inhibitor-induced bullous pemphigoid

Journal: Dermatologie (Heidelberg, Germany)
Published: February 11, 2026

Deep Phenotyping and Molecular Elucidation of a New Syndrome: Ectodermal Dysplasia Caused by IRF6 Variants.

Deep Phenotyping and Molecular Elucidation of a New Syndrome: Ectodermal Dysplasia Caused by IRF6 Variants.

Journal: Experimental dermatology
Published: February 10, 2026

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.

Journal: European journal of cancer (Oxford, England : 1990)
Published: January 25, 2026

Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.

Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.

Journal: European journal of cancer (Oxford, England : 1990)
Published: January 16, 2026
Showing 1-12 of 401

Last Updated: 09/26/2026